Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 12/2018

03.10.2018 | Original Article

The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study

verfasst von: Nesrin Ghanem-Zoubi, Danny Zorbavel, Johad Khoury, Yuval Geffen, Majd Qasum, Svetlana Predescu, Mical Paul

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

To evaluate the association between appropriate antifungal treatment and mortality among patients with candidemia using different breakpoint definitions. In a retrospective study, we included all adults with candidemia in a tertiary center between 2009 and 2015. We defined three versions of appropriate (covering) antifungal treatment, according to Clinical and Laboratory Standards Institute (CLSI) 2008, CLSI 2012, and European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2017 update) breakpoints. For empiric treatment, we evaluated the association with 30-day mortality. For definitive treatment, we evaluated the association with 90-day mortality among patients surviving the first week after candidemia onset. Adjusted odds ratios (OR) from a bivariate logistic regression with 95% confidence intervals are reported. We identified 302 patients with 308 separate candidemia episodes. The crude 30-day mortality was 55% (168/308). Resistance to anidulafungin increased from 3.5 to 51.6% and to fluconazole from 15.2 to 44.1%, when applying CLSI 2008 and EUCAST definitions, respectively. Appropriate empirical treatment was significantly associated with lower 30-day mortality using the CLSI 2008 definitions, adjusted OR 0.56 (0.33–0.96). The associations were similar, though not statistically significant for EUCAST, 0.58 (0.33–1.00), and CLSI 2012, OR 0.62 (0.37–1.04). Appropriate definitive treatment according to CLSI 2012 and EUCAST was independently associated with lower 90-day mortality, ORs 0.31 (0.13–0.75) and 0.44 (0.23–0.8), respectively. With CLSI 2008, the association was similar but not statistically significant, OR 0.4 (0.11–1.41), with few isolates classified as resistant. Considering the major shift in resistance prevalence when applying CLSI 2008, CLSI 2012, and EUCAST breakpoint definitions, no major differences were observed in their association with mortality.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
5.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI) (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts. : informat. Wayne, Pennsylvania 19087 USA Clinical and Laboratory Standards Institute (CLSI) (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts. : informat. Wayne, Pennsylvania 19087 USA
6.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI) (2012) Reference method for broth dilution antifungal susceptibility testing of yeasts. Fourth Inf. Wayne, Pennsylvania 19087 USA Clinical and Laboratory Standards Institute (CLSI) (2012) Reference method for broth dilution antifungal susceptibility testing of yeasts. Fourth Inf. Wayne, Pennsylvania 19087 USA
9.
Zurück zum Zitat Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW, European Committee on Antimicrobial Susceptibility Testing—Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) (2014) EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses 57:377–379. https://doi.org/10.1111/myc.12170 CrossRefPubMed Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW, European Committee on Antimicrobial Susceptibility Testing—Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) (2014) EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses 57:377–379. https://​doi.​org/​10.​1111/​myc.​12170 CrossRefPubMed
18.
Zurück zum Zitat Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Mühlethaler K et al (2014) Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect 20:698–705. https://doi.org/10.1111/1469-0691.12440 CrossRefPubMed Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Mühlethaler K et al (2014) Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect 20:698–705. https://​doi.​org/​10.​1111/​1469-0691.​12440 CrossRefPubMed
27.
Zurück zum Zitat Arendrup MC, Garcia-Effron G, Lass-Flörl C, Lopez AG, Rodriguez-Tudela J-L, Cuenca-Estrella M et al (2010) Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 54:426–439. https://doi.org/10.1128/AAC.01256-09 CrossRefPubMed Arendrup MC, Garcia-Effron G, Lass-Flörl C, Lopez AG, Rodriguez-Tudela J-L, Cuenca-Estrella M et al (2010) Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 54:426–439. https://​doi.​org/​10.​1128/​AAC.​01256-09 CrossRefPubMed
30.
Metadaten
Titel
The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study
verfasst von
Nesrin Ghanem-Zoubi
Danny Zorbavel
Johad Khoury
Yuval Geffen
Majd Qasum
Svetlana Predescu
Mical Paul
Publikationsdatum
03.10.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 12/2018
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3389-1

Weitere Artikel der Ausgabe 12/2018

European Journal of Clinical Microbiology & Infectious Diseases 12/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.